Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Status:
Terminated
Trial end date:
2018-11-05
Target enrollment:
Participant gender:
Summary
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine
and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib). The objective is to
assess tolerability and the resection rate of patients with borderline resectable pancreatic
adenocarcinoma who use this treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Novartis Novartis Pharmaceuticals The Skip Viragh Foundation